Abstract 4215: A comparative assessment of machine learning models for predicting prostate cancer using PVT1 biomarkers and PSA

Abstract Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men, especially in populations of African ancestry. While prostate-specific antigen (PSA) testing is the most common diagnostic tool, its low specificity results in overdiagnosis and overtreatment. Recent studies have shown that specific exons of the PVT1 gene, such as exon 4A, exon 4B and exon 9, may serve as promising biomarkers to improve PCa risk stratification when combined with PSA levels. Building on this work, our study evaluates the predictive accuracy of machine learning techniques in identifying patients with any prostate cancer or high-grade prostate cancer on data from 108 multiracial men with elevated PSA. We explore different combinations of these features using logistic regression and support vector machines (SVMs).We found no single best method across all population groups and endpoints. The optimal classifier varied based on the specific prediction task. For predicting any cancer in the general population, the best performing model was Logistic Regression (F1-score of 0.72) when PSA is combined with PVT1 exon 4a. For cancer grade prediction in the general population, SVM achieved the best performance (F1 score of 0.93) using PSA, PVT1 exon 4a and PVT1 exon 9. For predicting the risk of any cancer among Men of African Ancestry (MoAA) Logistic Regression achieved the best accuracy (F1 score of 0.89) by combining PSA with PVT1 exon 4a.Our results show that combination of PVT1 biomarkers with PSA improves the accuracy of risk prediction across different populations and endpoints. Additionally, Logistic Regression provides more accurate predictions of any cancer whereas SVMs perform better for predicting high grade cancer. Future work will focus on evaluating our models on larger clinical data Citation Format: Pragyan Kadel, Rachel E. Bonacci, Emmanuel Owusu Asante-Asamani, Olorunseun O. Ogunwobi. A comparative assessment of machine learning models for predicting prostate cancer using PVT1 biomarkers and PSA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4215.

Authors

Institutions

Publication Details

Journal
Cancer Research
Published
2026-04-03
DOI
https://doi.org/10.1158/1538-7445.am2026-4215
Primary Topic
Cardiovascular Health and Risk Factors
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract 4215: A comparative assessment of machine learning models for predicting prostate cancer using PVT1 biomarkers and PSA

Olorunseun O. Ogunwobi, Emmanuel Asante-Asamani, Rachel E. Bonacci, Pragyan Kadel
Cancer Research
Cardiovascular Health and Risk Factors
article

Abstract 4215: A comparative assessment of machine learning models for predicting prostate cancer using PVT1 biomarkers and PSA

Olorunseun O. Ogunwobi, Emmanuel Asante-Asamani, Rachel E. Bonacci, Pragyan Kadel
article en

Abstract

Abstract Prostate cancer (PCa) is one of the leading causes of cancer-related deaths among men, especially in populations of African ancestry. While prostate-specific antigen (PSA) testing is the most common diagnostic tool, its low specificity results in overdiagnosis and overtreatment. Recent studies have shown that specific exons of the PVT1 gene, such as exon 4A, exon 4B and exon 9, may serve as promising biomarkers to improve PCa risk stratification when combined with PSA levels. Building on this work, our study evaluates the predictive accuracy of machine learning techniques in identifying patients with any prostate cancer or high-grade prostate cancer on data from 108 multiracial men with elevated PSA. We explore different combinations of these features using logistic regression and support vector machines (SVMs).We found no single best method across all population groups and endpoints. The optimal classifier varied based on the specific prediction task. For predicting any cancer in the general population, the best performing model was Logistic Regression (F1-score of 0.72) when PSA is combined with PVT1 exon 4a. For cancer grade prediction in the general population, SVM achieved the best performance (F1 score of 0.93) using PSA, PVT1 exon 4a and PVT1 exon 9. For predicting the risk of any cancer among Men of African Ancestry (MoAA) Logistic Regression achieved the best accuracy (F1 score of 0.89) by combining PSA with PVT1 exon 4a.Our results show that combination of PVT1 biomarkers with PSA improves the accuracy of risk prediction across different populations and endpoints. Additionally, Logistic Regression provides more accurate predictions of any cancer whereas SVMs perform better for predicting high grade cancer. Future work will focus on evaluating our models on larger clinical data Citation Format: Pragyan Kadel, Rachel E. Bonacci, Emmanuel Owusu Asante-Asamani, Olorunseun O. Ogunwobi. A comparative assessment of machine learning models for predicting prostate cancer using PVT1 biomarkers and PSA [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 4215.

Cancer ResearchVol. 86(7_Supplement)
Clarkson University (US), Michigan State University (US)
Good health and well-being
Openalex Percentile: Top 5%
Cardiovascular Health and Risk Factors
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.